Is ARDX Worth Buying in 2026?

Ardelyx, Inc.

STOCK PHARMACEUTICAL PREPARATIONS Updated 2026-06-14

Here’s whether Ardelyx, Inc. (ARDX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Caution.

🟡
Caution

Positives: RSI 38 — healthy momentum range; strong 1-year return of +53.0%. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative). Currently 32.3% off its 52-week high. Score: -1/7.

Ready to act on this? 📈 Trade on Webull

ARDX is trading below its 200-day MA ($6.13) — a key warning sign the longer-term trend is under pressure. An RSI of 37.5 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +53.0% compares to +22.9% for SPY (beat the market by 30.1%). The current 32.3% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.

$10,000 invested 1 year ago → $15,296 today
vs. S&P 500 (SPY) — same period beat market by 30.1%

1-Year Price Chart

Daily candles
MA-50 MA-200 Up Down

Signal Check

Above 200-day MA ($6.13)
Above 50-day MA ($6.17)
RSI(14) neutral zone (30–70) — currently 37.5
Positive return (+53.0%)
!Within 10% of period high (−32.3%)
Period Range $5.69
$3.49 $8.40
RSI (14) 37.5
0 · OversoldOverbought · 100

Key Metrics

Price$5.69
Period Return+53.0%
Period High$8.40
Period Low$3.49
Drawdown−32.3%
MA-50$6.17
MA-200$6.13
RSI (14)37.5
Avg Volume (30d)3.8M
vs. SPYbeat by 30.1%
Return Rank#325 of 1246

Trade ARDX

📈 Trade on Webull 📊 Trade on moomoo 💹 Interactive Brokers